Home > Annual Financials > LYKA LABS

LYKA LABS Financial Statement Analysis
[BOM: 500259|NSE : LYKALABS]

The Revenues of LYKA LABS have increased by 125.02% YoY .
The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

LYKA LABS Last 5 Annual Financial Results
[BOM: 500259|NSE : LYKALABS]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹194 Cr₹86 Cr₹61 Cr₹71 Cr₹60 Cr
Expenses ₹93 Cr₹67 Cr₹65 Cr₹73 Cr₹63 Cr
Operating Profit (Excl OI) ₹101 Cr₹20 Cr₹-3.67 Cr₹-1.90 Cr₹-3.55 Cr
Other Income ₹2.09 Cr₹1.56 Cr₹3.09 Cr₹2.09 Cr₹2.13 Cr
Interest ₹20 Cr₹26 Cr₹20 Cr₹7.17 Cr₹9.58 Cr
Depreciation ₹17 Cr₹8.32 Cr₹8.01 Cr₹7.31 Cr₹11 Cr
Profit Before Tax ₹59 Cr₹-14 Cr₹-62 Cr₹-15 Cr₹-20 Cr
Profit After Tax ₹38 Cr₹-10 Cr₹-63 Cr₹-6.35 Cr₹-19 Cr
Consolidated Net Profit ₹39 Cr₹-12 Cr₹-61 Cr₹-5.55 Cr₹-17 Cr
Earnings Per Share (Rs)₹-4.30₹13.59₹-4.03₹-21.10₹-1.97
PAT Margin (%)-14.1319.81-11.70-101.84-8.97
ROE(%)-63.630.000.00-448.65-14.20
ROCE(%)-1.0056.688.95-31.39-5.50
Total Debt/Equity(x)2.589.76-6.30-9.852.28

Key Financials

Market Cap : ₹ 378.5 Cr
Revenue (TTM) : ₹ 105.7 Cr
Net Profit(TTM) : ₹ -3.5 Cr
EPS (TTM) : ₹ -1.1
P/E (TTM) : -

Industry Peers & Returns1W1M1Y
LYKA LABS -2% -11.4% 14.3%
SUN PHARMACEUTICAL INDUSTRIES 0.7% -4.8% 57.3%
CIPLA 1.9% -2.4% 42.6%
DR REDDYS LABORATORIES -5.4% -4.1% 20%
ZYDUS LIFESCIENCES 1.3% 0.5% 87.4%
DIVIS LABORATORIES 0.1% 3% 12.1%
MANKIND PHARMA -1.7% -7.8% 57.2%
TORRENT PHARMACEUTICALS -0.5% 1% 57.7%
LUPIN 4.8% 5.2% 115.9%


LYKA LABS Revenues
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

125.02 %

5 Yr CAGR

34.22 %

Years Revenues % Change
Mar2023 ₹194 Cr
125.02
Mar2022 ₹86 Cr
40.27
Mar2021 ₹61 Cr
-13.13
Mar2020 ₹71 Cr
18.35
Mar2019 ₹60 Cr -


LYKA LABS Operating Profit
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

413.90 %

5 Yr CAGR

Positive

Years Operating Profit % Change
Mar2023 ₹101 Cr
413.90
Mar2022 ₹20 Cr
Positive
Mar2021 ₹-3.67 Cr
Negative
Mar2020 ₹-1.90 Cr
Negative
Mar2019 ₹-3.55 Cr -

Operating Margins
Y-o-Y

128.40 %

5 Yr CAGR

Positive

Years Operating Margin% % Change
Mar2023 52.12%
128.40
Mar2022 22.82%
Positive
Mar2021 -5.97%
Negative
Mar2020 -2.68%
Negative
Mar2019 -5.94% -

LYKA LABS Profit After Tax
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Positive

5 Yr CAGR

Positive

Years Profit After Tax % Change
Mar2023 ₹39 Cr
Positive
Mar2022 ₹-12 Cr
Negative
Mar2021 ₹-61 Cr
Negative
Mar2020 ₹-5.55 Cr
Negative
Mar2019 ₹-17 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2023 -14.13 %
Negative
Mar2022 19.81 %
Positive
Mar2021 -11.7 %
Negative
Mar2020 -101.84 %
Negative
Mar2019 -8.97 % -

LYKA LABS Earnings Per Share (EPS)
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2023 ₹-4.30
Negative
Mar2022 ₹14
Positive
Mar2021 ₹-4.03
Negative
Mar2020 ₹-21
Negative
Mar2019 ₹-1.97 -

LYKA LABS Return on Capital Employed (ROCE)
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years ROCE % Change
Mar2023 -1%
Negative
Mar2022 56.68%
533.30
Mar2021 8.95%
Positive
Mar2020 -31.39%
Negative
Mar2019 -5.5% -

LYKA LABS Share Price vs Sensex

Current Share Price : ₹114.4
Current MarketCap: ₹ 378.5 Cr
Updated EOD on :May 13,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
LYKA LABS

-2%

-11.4%

14.3%

SENSEX

-1.5%

-2.6%

17.8%

LYKA LABS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about LYKA LABS Financials


How the annual revenues of LYKA LABS have changed ?

The Revenues of LYKA LABS have increased by 125.02% YoY .

How the Earnings per Share (EPS) of LYKA LABS have changed?

The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY .